3 天前 - … with chemotherapy for recurrent or metastatic squamous cell carcinoma of the
head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394: …

5 天前 - … squamous cell carcinoma of the head and neck with distant metastasis or recurrence
which was not amenable to curative locoregional treatment, refractory or intolerant to both …

8 天前 - … locally advanced head and neck squamous cell carcinoma (… ‑EGFR monoclonal
antibody cetuximab was evaluated in … the effec‑ tiveness of cetuximab plus RT in the treatment …

8 天前 - … or metastatic head and neck squamous cell carcinoma (R/M … cetuximab-based
treatment. Methods: Cohorts were … +CT), and patients treated with cetuximab and platinum+5-FU …

8 天前 - … ) in multiple solid tumor cohorts (NCT04485013… head and neck squamous cell
carcinoma (HNSCC) and WT RAS/BRAF, HER2-Neg metastatic colorectal cancer (mCRC) tumors…

8 天前 - … Here we present updated interim evaluation findings based on a recent data cut
from this study initially presented at the 2023 American Head and Neck Society meeting. …

8 天前 - … , carboplatin, and cetuximab followed by chemoradiotherapy (CRT) from 2013 to
2022 in our hospital. Two radiologists specializing in head and neck cancer blindly annotated …

8 天前 - … ≤2 prior lines of systemic therapy (median: 2; range: 1-3), 40 (100%) pts received
prior CPI, 23 (57.5%) pts received prior taxane, and 27 (67.5%) pts received prior cetuximab. …

8 天前 - … HNSCC pts across different primary tumor sites, with an ORR 56%, including
those with prior taxane exposure. A phase 2 study of FID with cetuximab in pts with HNSCC is …

8 天前 - … Conclusions: The use of IO less than 3 months before cetuximab lead to better
ORR to cetuximab compared to a delay longer than 3 months. When cetuximab is started early …